Clinical Trial Update: A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating autologous tumor-infiltrating lymphocytes edited by CRISPR to inhibit CISH for metastatic gastrointestinal cancers has been complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Esophageal Cancer
• Gallbladder Cancer
• Gastric Cancer
• Gastrointestinal Cancer
• Pancreatic Cancer

Drugs mentioned

• Tumor Infiltrating Lymphocytes (TIL) therapy with CISH CRISPR editing

Snippet

Sponsor: Intima Bioscience, Inc. | Conditions: Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms | Phase 1, Phase 2 | Status: COMPLETED